European life sciences venture capital firm Sofinnova Partners has announced the closing of their oversubscribed late-stage healthcare crossover fund at €445 Million ($540m). This now comprises the largest crossover investor dedicated late-stage biopharma and Medtech fund in Europe.

Paris, London, and Milan-based firm said that the fund was "oversubscribed and sig